The role of Fusobacteria in oral cancer and immune evasion.
Journal
Current opinion in oncology
ISSN: 1531-703X
Titre abrégé: Curr Opin Oncol
Pays: United States
ID NLM: 9007265
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
pubmed:
13
1
2023
medline:
3
2
2023
entrez:
12
1
2023
Statut:
ppublish
Résumé
There is growing evidence that suggests a possible role for bacteria in the progression of cancer. Fusobacteria have been detected in different types of cancers, including colorectal and oral cancers. Fusobacteria are common opportunistic oral bacteria known to cause various infections. In this review, we focus on the association between Fusobacteria and cancer, specifically oral cancer, and provide insight into the role of Fusobacteria in carcinogenesis and immune evasion. Recently, it has been suggested that Fusobacteria are among the bacteria that contribute to the progression of cancer and might affect disease prognosis and treatment outcome. Moreover, Fusobacteria might alter tumor microenvironment and have an impact on tumor immune response. Thus, understanding the effect of Fusobacteria on cancer cells and tumor microenvironment is crucial to improve treatment outcome. Recent evidences suggest that Fusobacteria not only have an impact on tumor progression, but might also affect tumor immune response. Moreover, Fusobacteria presence in the tumor microenvironment might have an impact on treatment outcome and might be used as a prognostic factor.
Identifiants
pubmed: 36633319
doi: 10.1097/CCO.0000000000000927
pii: 00001622-202303000-00008
doi:
Types de publication
Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
125-131Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008; 371:1695–1709.
Rhodus NL. Oral cancer and precancer: improving outcomes. Compend Contin Educ Dent 2009; 30:486–488. 90-4, 96-8 passim; quiz 504, 20.
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71:209–249.
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022; 72:7–33.
Day TA, Davis BK, Gillespie MB, et al. Oral cancer treatment. Curr Treat Options Oncol 2003; 4:27–41.
Laronde JPaDM. Treatment modalities of oral cancer. Can J Dent Hyg 2014; 48:13–19.
Tezal M, Sullivan MA, Reid ME, et al. Chronic periodontitis and the risk of tongue cancer. Arch Otolaryngol Head Neck Surg 2007; 133:450–454.
Tezal M, Grossi SG, Genco RJ. Is periodontitis associated with oral neoplasms? J Periodontol 2005; 76:406–410.
Meyer MS, Joshipura K, Giovannucci E, Michaud DS. A review of the relationship between tooth loss, periodontal disease, and cancer. Cancer Causes Control 2008; 19:895–907.
Rajesh KS, Thomas D, Hegde S, Kumar MS. Poor periodontal health: a cancer risk? J Indian Soc Periodontol 2013; 17:706–710.
Holmes S. The oral complications of specific anticancer therapy. Int J Nurs Stud 1991; 28:343–360.
Hashemi Goradel N, Heidarzadeh S, Jahangiri S, et al. Fusobacterium nucleatum and colorectal cancer: a mechanistic overview. J Cell Physiol 2019; 234:2337–2344.
Moore WE, Moore LV. The bacteria of periodontal diseases. Periodontol 2000 1994; 5:66–77.
Didilescu AC, Rusu D, Anghel A, et al. Investigation of six selected bacterial species in endo-periodontal lesions. Int Endod J 2012; 45:282–293.
Swidsinski A, Dörffel Y, Loening-Baucke V, et al. Acute appendicitis is characterised by local invasion with Fusobacterium nucleatum/necrophorum. Gut 2011; 60:34–40.
Tahara T, Shibata T, Kawamura T, et al. Fusobacterium detected in colonic biopsy and clinicopathological features of ulcerative colitis in Japan. Dig Dis Sci 2015; 60:205–210.
Témoin S, Chakaki A, Askari A, et al. Identification of oral bacterial DNA in synovial fluid of patients with arthritis with native and failed prosthetic joints. J Clin Rheumatol 2012; 18:117–121.
Han YW, Fardini Y, Chen C, et al. Term stillbirth caused by oral Fusobacterium nucleatum. Obstet Gynecol 2010; 115 (Pt 2):442–445.
Brook I. Fusobacterial infections in children. Curr Infect Dis Rep 2013; 15:288–294.
Zhao T, Wang X, Fu L, Yang K. Fusobacterium nucleatum: a new player in regulation of cancer development and therapeutic response. Cancer Drug Resist 2022; 5:436–450.
Yamamura K, Baba Y, Nakagawa S, et al. Human microbiome fusobacterium nucleatum in esophageal cancer tissue is associated with prognosis. Clin Cancer Res 2016; 22:5574–5581.
Del Castillo E, Meier R, Chung M, et al. The microbiomes of pancreatic and duodenum tissue overlap and are highly subject specific but differ between pancreatic cancer and noncancer subjects. Cancer Epidemiol Biomarkers Prev 2019; 28:370–383.
Holt RA, Cochrane K. Tumor potentiating mechanisms of Fusobacterium nucleatum , A Multifaceted Microbe. Gastroenterology 2017; 152:694–696.
Ito M, Kanno S, Nosho K, et al. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway. Int J Cancer 2015; 137:1258–1268.
Park CH, Han DS, Oh YH, et al. Role of Fusobacteria in the serrated pathway of colorectal carcinogenesis. Sci Rep 2016; 6:25271.
Tran HNH, Thu TNH, Nguyen PH, et al. Tumour microbiomes and Fusobacterium genomics in Vietnamese colorectal cancer patients. NPJ Biofilms Microbiomes 2022; 8:87.
Bullman S, Pedamallu CS, Sicinska E, et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 2017; 358:1443–1448.
Nagy KN, Sonkodi I, Szöke I, et al. The microflora associated with human oral carcinomas. Oral Oncol 1998; 34:304–308.
Al-Hebshi NN, Nasher AT, Maryoud MY, et al. Inflammatory bacteriome featuring Fusobacterium nucleatum and Pseudomonas aeruginosa identified in association with oral squamous cell carcinoma. Sci Rep 2017; 7:1834.
Shin JM, Luo T, Kamarajan P, et al. Microbial communities associated with primary and metastatic head and neck squamous cell carcinoma – a high fusobacterial and low streptococcal signature. Sci Rep 2017; 7:9934.
Chang C, Geng F, Shi X, et al. The prevalence rate of periodontal pathogens and its association with oral squamous cell carcinoma. Appl Microbiol Biotechnol 2019; 103:1393–1404.
Bronzato JD, Bomfim RA, Edwards DH, et al. Detection of Fusobacterium in oral and head and neck cancer samples: a systematic review and meta-analysis. Arch Oral Biol 2020; 112:104669.
Ganly I, Yang L, Giese RA, et al. Periodontal pathogens are a risk factor of oral cavity squamous cell carcinoma, independent of tobacco and alcohol and human papillomavirus. Int J Cancer 2019; 145:775–784.
Yu T, Guo F, Yu Y, et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 2017; 170:548–563. e16.
Zhang S, Yang Y, Weng W, et al. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer. J Exp Clin Cancer Res 2019; 38:14.
Yang Y, Weng W, Peng J, et al. Fusobacterium nucleatum increases proliferation of colorectal cancer cells and tumor development in mice by activating toll-like receptor 4 signaling to nuclear factor-kappa B, and up-regulating expression of microRNA-21. Gastroenterology 2017; 152:856.e24–866.e24.
Rubinstein MR, Wang X, Liu W, et al. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe 2013; 14:195–206.
Uitto VJ, Baillie D, Wu Q, et al. Fusobacterium nucleatum increases collagenase 3 production and migration of epithelial cells. Infect Immun 2005; 73:1171–1179.
Kostic AD, Chun E, Robertson L, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013; 14:207–215.
Udayasuryan B, Ahmad RN, Nguyen TTD, et al. Fusobacterium nucleatum induces proliferation and migration in pancreatic cancer cells through host autocrine and paracrine signaling. Sci Signal 2022; 15:eabn4948.
Tang B, Wang K, Jia YP, et al. Fusobacterium nucleatum -induced impairment of autophagic flux enhances the expression of proinflammatory cytokines via ROS in Caco-2 cells. PLoS One 2016; 11:e0165701.
Lu P, Xu M, Xiong Z, Zhou F. Wang L. prevents apoptosis in colorectal cancer cells via the ANO1 pathway. Cancer Manag Res 2019; 11:9057–9066.
Nosho K, Sukawa Y, Adachi Y, et al. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. World J Gastroenterol 2016; 22:557–566.
Xu Q, Lu X, Li J, et al. Fusobacterium nucleatum induces excess methyltransferase-like 3-mediated microRNA-4717-3p maturation to promote colorectal cancer cell proliferation. Cancer Sci 2022; 113:3787–3800.
2021; Despins CA, Brown SD, Robinson AV, et al. Modulation of the host cell transcriptome and epigenome by Fusobacterium nucleatum . mBio. 12:e0206221.
Binder Gallimidi A, Fischman S, Revach B, et al. Periodontal pathogens Porphyromonas gingivalis and Fusobacterium nucleatum promote tumor progression in an oral-specific chemical carcinogenesis model. Oncotarget 2015; 6:22613–22623.
Geng F, Zhang Y, Lu Z, et al. Caused DNA damage and promoted cell proliferation by the DNA. Cell Biol 2020; 39:144–151.
Harrandah AM, Chukkapalli SS, Bhattacharyya I, et al. Fusobacteria modulate oral carcinogenesis and promote cancer progression. J Oral Microbiol 2020; 13:1849493.
Yamamura K, Izumi D, Kandimalla R, et al. Intratumoral. Clin Cancer Res 2019; 25:6170–6179.
Lu H, Ren Z, Li A, et al. Tongue coating microbiome data distinguish patients with pancreatic head cancer from healthy controls. J Oral Microbiol 2019; 11:1563409.
Mitsuhashi K, Nosho K, Sukawa Y, et al. Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Oncotarget 2015; 6:7209–7220.
Deng X, Li Z, Li G, et al. Comparison of microbiota in patients treated by surgery or chemotherapy by 16S rRNA sequencing reveals potential biomarkers for colorectal cancer therapy. Front Microbiol 2018; 9:1607.
Mima K, Nishihara R, Qian ZR, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut 2016; 65:1973–1980.
Zhang X, Zhang Y, Gui X, et al. Salivary Fusobacterium nucleatum serves as a potential biomarker for colorectal cancer. iScience 2022; 25:104203.
Chen WD, Zhang X, Zhang MJ, et al. Salivary Fusobacterium nucleatum serves as a potential diagnostic biomarker for gastric cancer. World J Gastroenterol 2022; 28:4120–4132.
Desai S, Dharavath B, Manavalan S, et al. Fusobacterium nucleatum is associated with inflammation and poor survival in early-stage HPV-negative tongue cancer. NAR Cancer 2022; 4:zcac006.
Neuzillet C, Marchais M, Vacher S, et al. Prognostic value of intratumoral Fusobacterium nucleatum and association with immune-related gene expression in oral squamous cell carcinoma patients. Sci Rep 2021; 11:7870.
Xue Y, Xiao H, Guo S, et al. Indoleamine 2,3-dioxygenase expression regulates the survival and proliferation of Fusobacterium nucleatum in THP-1-derived macrophages. Cell Death Dis 2018; 9:355.
Chen T, Li Q, Wu J, et al. Fusobacterium nucleatum promotes M2 polarization of macrophages in the microenvironment of colorectal tumours via a TLR4-dependent mechanism. Cancer Immunol Immunother 2018; 67:1635–1646.
Ye X, Wang R, Bhattacharya R, et al. Fusobacterium nucleatum subspecies animalis influences proinflammatory cytokine expression and monocyte activation in human colorectal tumors. Cancer Prev Res (Phila) 2017; 10:398–409.
Wu J, Wang Y, Jiang Z. Immune induction identified by TMT proteomics analysis in. Expert Rev Proteomics 2020; 17:175–185.
Wu J, Li Q, Fu X. Fusobacterium nucleatum contributes to the carcinogenesis of colorectal cancer by inducing inflammation and suppressing host immunity. Transl Oncol 2019; 12:846–851.
Mima K, Sukawa Y, Nishihara R, et al. Fusobacterium nucleatum and T cells in colorectal carcinoma. JAMA Oncol 2015; 1:653–661.
Gur C, Ibrahim Y, Isaacson B, et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 2015; 42:344–355.
Coombes JL, Siddiqui KR, Arancibia-Cárcamo CV, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 2007; 204:1757–1764.
Gao Y, Bi D, Xie R, et al. Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer. Signal Transduct Target Ther 2021; 6:398.
Michikawa C, Gopalakrishnan V, Harrandah AM, et al. Fusobacterium is enriched in oral cancer and promotes induction of programmed death-ligand 1 (PD-L1). Neoplasia 2022; 31:100813.
Alon-Maimon T, Mandelboim O, Bachrach G. Fusobacterium nucleatum and cancer. Periodontol 2000 2022; 89:166–180.